Septerna, Inc. (SEPN)
| Market Cap | 1.43B +254.7% |
| Revenue (ttm) | 72.26M +7,295.6% |
| Net Income | -36.04M |
| EPS | -0.81 |
| Shares Out | 45.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,633 |
| Open | 31.97 |
| Previous Close | 31.15 |
| Day's Range | 31.77 - 32.00 |
| 52-Week Range | 9.70 - 32.63 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 44.25 (+39.28%) |
| Earnings Date | May 11, 2026 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM f... [Read more]
Financial Performance
In 2025, Septerna's revenue was $45.95 million, an increase of 4174.51% compared to the previous year's $1.08 million. Losses were -$48.88 million, -31.92% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SEPN stock is "Strong Buy." The 12-month stock price target is $44.25, which is an increase of 39.28% from the latest price.
News
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
Septerna Transcript: Bank of America Global Healthcare Conference 2026
Two lead GPCR-targeting programs are advancing in clinical trials, with SEP-479 in phase I for hypoparathyroidism and SEP-631 moving to phase II for urticaria. The proprietary platform enables rapid discovery of novel drug candidates, and the pipeline includes additional programs for Graves' disease and incretin agonists.
Septerna reports Q1 EPS (19c), consensus (27c)
Reports Q1 revenue $26.52M, consensus $15.09M. “In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the...
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026
Septerna Earnings release: Q1 2026
Septerna released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Septerna Quarterly report: Q1 2026
Septerna has published its Q1 2026 quarterly earnings report on May 11, 2026.
Septerna to Present at Bank of America Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disco...
Septerna initiated with a Buy at Stifel
Stifel analyst Alex Thompson initiated coverage of Septerna (SEPN) with a Buy rating and $43 price target The firm is bullish on Septerna’s G protein-coupled receptors drug discovery platform. The…
Septerna Proxy statement: Proxy filing
Septerna filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Septerna Proxy statement: Proxy filing
Septerna filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Septerna doses first patients in SEP-479 trial
Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist being developed for the treatment of patients…
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers
Septerna price target raised to $38 from $34 at JPMorgan
JPMorgan raised the firm’s price target on Septerna (SEPN) to $38 from $34 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4…
Septerna price target raised to $35 from $34 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Septerna (SEPN) to $35 from $34 and keeps a Buy rating on the shares. The firm is incrementally positive on…
Septerna files automatic mixed securities shelf
16:33 EDT Septerna (SEPN) files automatic mixed securities shelf
Septerna reports Q4 EPS (24c), consensus (22c)
Reports Q4 revenue $24.12M, consensus $15.56M. “We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase 1 results...
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R ...
Septerna Annual report: Q4 2025
Septerna has published its Q4 2025 annual report on March 9, 2026.
Septerna Earnings release: Q4 2025
Septerna released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Septerna Transcript: TD Cowen 46th Annual Health Care Conference
SEP-631 showed robust phase I results and will enter a 12-week, dose-ranging phase II trial for chronic spontaneous urticaria in the second half of the year. SEP-479, an oral PTH agonist, is set to begin phase I trials soon, with titration and monitoring strategies to be refined in later phases.
Septerna Slides: Corporate presentation
Septerna has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Septerna price target raised to $40 from $35 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Septerna (SEPN) to $40 from $35 and keeps a Buy rating on the shares after the company presented data from the Phase…
Septerna Transcript: Study result
SEP-631 demonstrated a favorable safety profile and robust, dose-dependent inhibition of MRGPRX2 signaling in a phase I trial, supporting once-daily oral dosing without food restrictions. These results validate clinical proof of mechanism and support advancement into phase II studies for chronic spontaneous urticaria and other mast cell-driven diseases.
Septerna Press release: Study result
Septerna issued a press release on March 2, 2026, disclosing material business information to investors.
Septerna Slides: Study result
Septerna has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.